<?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName art560.dtd?>
<?SourceDTD.Version 5.6.0?>
<?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?origin publisher?>
<?FILEmeta_JVAC24743 xml ?>
<?FILEmain xml ?>
<?FILEgr1 jpg ?>
<?FILEgr2 jpg ?>
<?FILEgr3 jpg ?>
<?FILEgr4 jpg ?>
<?FILEfx1 jpg ?>
<?FILEfx2 jpg ?>
<?FILEmmc1 docx ?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Vaccine</journal-id>
    <journal-id journal-id-type="iso-abbrev">Vaccine</journal-id>
    <journal-title-group>
      <journal-title>Vaccine</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0264-410X</issn>
    <issn pub-type="epub">1873-2518</issn>
    <publisher>
      <publisher-name>Elsevier Science</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10015272</article-id>
    <article-id pub-id-type="pii">S0264-410X(23)00162-7</article-id>
    <article-id pub-id-type="doi">10.1016/j.vaccine.2023.02.027</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Use of existing systematic reviews for the development of evidence-based vaccination recommendations: Guidance from the SYSVAC expert panel</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="au005">
        <name>
          <surname>Pilic</surname>
          <given-names>Antonia</given-names>
        </name>
        <email>pilica@rki.de</email>
        <xref rid="af005" ref-type="aff">a</xref>
        <xref rid="fn1" ref-type="fn">1</xref>
        <xref rid="cor1" ref-type="corresp">⁎</xref>
      </contrib>
      <contrib contrib-type="author" id="au010">
        <name>
          <surname>Reda</surname>
          <given-names>Sarah</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
        <xref rid="fn1" ref-type="fn">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au015">
        <name>
          <surname>Jo</surname>
          <given-names>Catherine L.</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
        <xref rid="fn1" ref-type="fn">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au020">
        <name>
          <surname>Burchett</surname>
          <given-names>Helen</given-names>
        </name>
        <xref rid="af010" ref-type="aff">b</xref>
      </contrib>
      <contrib contrib-type="author" id="au025">
        <name>
          <surname>Bastías</surname>
          <given-names>Magdalena</given-names>
        </name>
        <xref rid="af015" ref-type="aff">c</xref>
      </contrib>
      <contrib contrib-type="author" id="au030">
        <name>
          <surname>Campbell</surname>
          <given-names>Pauline</given-names>
        </name>
        <xref rid="af020" ref-type="aff">d</xref>
      </contrib>
      <contrib contrib-type="author" id="au035">
        <name>
          <surname>Gamage</surname>
          <given-names>Deepa</given-names>
        </name>
        <xref rid="af025" ref-type="aff">e</xref>
      </contrib>
      <contrib contrib-type="author" id="au040">
        <name>
          <surname>Henaff</surname>
          <given-names>Louise</given-names>
        </name>
        <xref rid="af030" ref-type="aff">f</xref>
      </contrib>
      <contrib contrib-type="author" id="au045">
        <name>
          <surname>Kagina</surname>
          <given-names>Benjamin</given-names>
        </name>
        <xref rid="af035" ref-type="aff">g</xref>
      </contrib>
      <contrib contrib-type="author" id="au050">
        <name>
          <surname>Külper-Schiek</surname>
          <given-names>Wiebe</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author" id="au055">
        <name>
          <surname>Lunny</surname>
          <given-names>Carole</given-names>
        </name>
        <xref rid="af040" ref-type="aff">h</xref>
      </contrib>
      <contrib contrib-type="author" id="au060">
        <name>
          <surname>Marti</surname>
          <given-names>Melanie</given-names>
        </name>
        <xref rid="af030" ref-type="aff">f</xref>
      </contrib>
      <contrib contrib-type="author" id="au065">
        <name>
          <surname>Muloiwa</surname>
          <given-names>Rudzani</given-names>
        </name>
        <xref rid="af035" ref-type="aff">g</xref>
      </contrib>
      <contrib contrib-type="author" id="au070">
        <name>
          <surname>Pieper</surname>
          <given-names>Dawid</given-names>
        </name>
        <xref rid="af045" ref-type="aff">i</xref>
        <xref rid="af060" ref-type="aff">l</xref>
      </contrib>
      <contrib contrib-type="author" id="au075">
        <name>
          <surname>Thomas</surname>
          <given-names>James</given-names>
        </name>
        <xref rid="af050" ref-type="aff">j</xref>
      </contrib>
      <contrib contrib-type="author" id="au080">
        <name>
          <surname>Tunis</surname>
          <given-names>Matthew C.</given-names>
        </name>
        <xref rid="af055" ref-type="aff">k</xref>
      </contrib>
      <contrib contrib-type="author" id="au085">
        <name>
          <surname>Younger</surname>
          <given-names>Zane</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author" id="au090">
        <name>
          <surname>Wichmann</surname>
          <given-names>Ole</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author" id="au095">
        <name>
          <surname>Harder</surname>
          <given-names>Thomas</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
      </contrib>
      <aff id="af005"><label>a</label>Robert Koch Institute, Seestrasse 10, 13353 Berlin, Germany</aff>
      <aff id="af010"><label>b</label>Faculty of Public Health &amp; Policy, London School of Hygiene and Tropical Medicine (LSHTM), 15-17 Tavistock Place, London WC1H 9SH, United Kingdom</aff>
      <aff id="af015"><label>c</label>Independent Consultant, Santiago, Chile</aff>
      <aff id="af020"><label>d</label>Nursing, Midwifery and Allied Health Professions Research Unit, Glasgow Caledonian University, Govan Mbeki Building, Glasgow G4 0BA, United Kingdom</aff>
      <aff id="af025"><label>e</label>Epidemiology Unit and Advisory Committee on Communicable Diseases, Ministry of Health, #231, De Saram Place, Colombo 10, Sri Lanka</aff>
      <aff id="af030"><label>f</label>World Health Organization, Avenue Appia 20, 1211 Geneva, Switzerland</aff>
      <aff id="af035"><label>g</label>University of Cape Town, Faculty of Health Sciences, Observatory, 7925 Cape Town, South Africa</aff>
      <aff id="af040"><label>h</label>Knowledge Translation Program, St Michael’s Hospital, Unity Health Toronto, and Cochrane Hypertension Review Group, University of British Columbia, 2176 Health Sciences Mall, Vancouver, BC V6T1Z2, Canada</aff>
      <aff id="af045"><label>i</label>Brandenburg Medical School Theodor Fontane, Faculty of Health Sciences Brandenburg, Institute for Health Services and Health System Research, 15562 Rüdersdorf bei Berlin, Germany</aff>
      <aff id="af050"><label>j</label>Evidence for Policy and Practice Information and Co-ordinating (EPPI-) Centre, UCL Social Research Institute, University College London, 10 Woburn Square, London WC1H 0NR, United Kingdom</aff>
      <aff id="af055"><label>k</label>Public Health Agency of Canada, Centre for Immunization Readiness, 130 Colonnade Road, A.L. 6501H, Ottawa, Ontario K1A 0K9, Canada</aff>
      <aff id="af060"><label>l</label>Brandenburg Medical School Theodor Fontane, Center for Health Services Research, 15562 Rüdersdorf bei Berlin, Germany</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>⁎</label>Corresponding author. <email>pilica@rki.de</email></corresp>
      <fn id="fn1">
        <label>1</label>
        <p id="np005">These authors contributed equally to the manuscript.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>17</day>
      <month>3</month>
      <year>2023</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.-->
    <pub-date pub-type="ppub">
      <day>17</day>
      <month>3</month>
      <year>2023</year>
    </pub-date>
    <volume>41</volume>
    <issue>12</issue>
    <fpage>1968</fpage>
    <lpage>1978</lpage>
    <history>
      <date date-type="received">
        <day>5</day>
        <month>12</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>8</day>
        <month>2</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>9</day>
        <month>2</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2023 Published by Elsevier Ltd.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder/>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/3.0/</ali:license_ref>
        <license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).</license-p>
      </license>
    </permissions>
    <abstract id="ab005">
      <p>National immunization technical advisory groups (NITAGs) develop immunization-related recommendations and assist policy-makers in making evidence informed decisions. Systematic reviews (SRs) that summarize the available evidence on a specific topic are a valuable source of evidence in the development of such recommendations. However, conducting SRs requires significant human, time, and financial resources, which many NITAGs lack. Given that SRs already exist for many immunization-related topics, and to prevent duplication and overlap of reviews, a more practical approach may be for NITAGs to use existing SRs. Nevertheless, it can be challenging to identify relevant SRs, to select one SR from among multiple SRs, or to critically assess and effectively use them.</p>
      <p>To support NITAGs, the London School of Hygiene and Tropical Medicine, Robert Koch Institute and collaborators developed the SYSVAC project, which consists of an online registry of systematic reviews on immunization-related topics and an e-learning course, that supports the use of them (both freely accessible at <ext-link ext-link-type="uri" xlink:href="https://www.nitag-resource.org/sysvac-systematic-reviews" id="ir005">https://www.nitag-resource.org/sysvac-systematic-reviews</ext-link>). Drawing from the e-learning course and recommendations from an expert panel, this paper outlines methods for using existing systematic reviews when making immunization-related recommendations. With specific examples and reference to the SYSVAC registry and other resources, it offers guidance on locating existing systematic reviews; assessing their relevance to a research question, up-to-dateness, and methodological quality and/or risk of bias; and considering the transferability and applicability of their findings to other populations or settings.</p>
    </abstract>
    <kwd-group id="kg005">
      <title>Keywords</title>
      <kwd>Evidence-based medicine</kwd>
      <kwd>Immunization recommendation</kwd>
      <kwd>Methodology</kwd>
      <kwd>Systematic review</kwd>
      <kwd>Vaccination</kwd>
    </kwd-group>
  </article-meta>
</front>
<body>
  <sec id="s0005">
    <label>1</label>
    <title>Introduction</title>
    <sec id="s0010">
      <label>1.1</label>
      <title>Background</title>
      <p id="p0025">National immunization technical advisory groups (NITAGs) are panels of experts that provide evidence-based recommendations to policy-makers and program managers in their countries on immunization-related issues <xref rid="b0005" ref-type="bibr">[1]</xref>. They hail from a variety of disciplines, including clinical medicine, epidemiology, infectious diseases, public health, immunology, clinical research, health economics, health systems, and social sciences. The work of NITAGs is ideally supported by a technical secretariat and funded predominantly by government and/or partner organizations <xref rid="b0005" ref-type="bibr">[1]</xref>. Despite this support, NITAGs, particularly in less resourced countries, are often pressed for technical resources in evidence reviewing when fulfilling their mandate.</p>
      <p id="p0030">NITAGs draw on empirical evidence when developing the recommendations for vaccination policies in their respective country. Systematic reviews (SRs) are a useful evidence source, particularly for questions on the benefits and harms of interventions as on vaccine efficacy, effectiveness, duration of protection, and safety. SRs provide a comprehensive summary of the evidence in a given area <xref rid="b0010" ref-type="bibr">[2]</xref>. They use systematic and transparent methods to identify all studies that are potentially relevant to a research question, select studies for inclusion, appraise the quality of included studies, and synthesize study results. By compiling available data, they provide more precise estimates of intervention effects than single studies <xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0020" ref-type="bibr">[4]</xref>, yet they can vary considerably in the quality and standard of SRs. <bold>Appendix 1,</bold>
<xref rid="s0005" ref-type="sec">Table S1</xref> presents an overview of different types of reviews to distinguish SRs from other types of reviews and evidence syntheses.</p>
      <p id="p0035">Historically, NITAGs have conducted or commissioned SRs on similar areas in the field of vaccination, increasing the potential for duplication and overlap <xref rid="b0025" ref-type="bibr">[5]</xref>. To prevent duplication and given the significant time, training, and expertise needed to conduct <italic>de novo</italic> SRs, a more efficient use of NITAGs’ limited resources may be to make greater use of already existing SRs. If a high-quality SR for the question of interest exists, NITAGs may be able to focus their time and efforts on applying the findings of the existing SR to their local contexts and gathering other policy-relevant information (e.g., stakeholder input) <xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0020" ref-type="bibr">[4]</xref>. However, it is not always easy to identify existing SRs that match a decision-maker’s research question or to select one SR from among multiple SRs.</p>
      <p id="p0040">The specific objectives are (a) to highlight relevant resources and tools for using existing SRs and (b) to propose considerations to be taken into account when searching for and using existing SRs. Key factors to consider are summarized in flowcharts that can be used as tools to identify which SR may be favored. The paper is not intended to be a comprehensive guide to using existing SRs (e.g., using data from <italic>meta</italic>-analyses or extraction tables) or to replace established or mandated processes of evidence-based decision-making (e.g., GRADE (Grading of Recommendations Assessment, Development and Evaluation)). The intended audiences are NITAG members, NITAG Secretariats, and experts globally involved in the development of recommendations on the vaccination and immunization policies. This guidance and the examples focus on SRs of quantitative studies, particularly those investigating the efficacy, effectiveness, and safety of vaccines. However, the outlined steps can be applied also to SRs of qualitative studies as well, for example, on topics such as vaccine coverage and administration.</p>
      <p id="p0045">The optimal process for reaching the best evidence-based recommendations may vary from country to country and local settings.</p>
    </sec>
    <sec id="s0015">
      <label>1.2</label>
      <title>Development of this guidance</title>
      <p id="p0050">In December 2019, the Robert Koch Institute (RKI) hosted an International Experts Workshop on “Methods for Using Systematic Reviews” <xref rid="b0030" ref-type="bibr">[6]</xref>, during which an international expert panel of immunization experts and methodologists of NITAGs and their secretariats (Australia, Canada, Chile, China, Germany, South Africa, Sri Lanka, USA), multilateral organizations (World Health Organization (WHO), ECDC), and academia (Glasgow Caledonian University, London School of Hygiene and Tropical Medicine (LSHTM), University College London, University of British Colombia, University of Cape Town, Witten/Herdecke University) shared experiences and reached consensus on methods for using SRs. Results of the workshop informed the further development of the SYSVAC registry, originally developed by the LSHTM and hosted by WHO <xref rid="b0025" ref-type="bibr">[5]</xref>, and establishment of the accompanying e-learning course on the use of existing SRs when developing recommendations (both now freely available at <ext-link ext-link-type="uri" xlink:href="https://www.nitag-resource.org/sysvac-systematic-reviews" id="ir010">https://www.nitag-resource.org/sysvac-systematic-reviews</ext-link>). The SYSVAC registry aims to facilitate NITAGs’ retrieval of SRs by compiling SRs on immunization-related topics and enabling filtering by country, region, disease/pathogen, publication date, and target population. It additionally provides methodological quality assessments for SRs and other information that may aid NITAGs in their selection of SRs to use (e.g., date of last literature search, number of studies). The e-learning course includes exercises and handouts intended to help NITAGs deepen and refresh their knowledge on using SRs. This paper summarizes recommendations of the SYSVAC expert panel and highlights how NITAGs can use the SYSVAC online registry in the recommendation-making process.</p>
    </sec>
  </sec>
  <sec id="s0020">
    <label>2</label>
    <title>Steps for using existing systematic reviews</title>
    <p id="p0055">The following six steps provide guidance on the use of existing SRs in the development of evidence-based vaccination recommendations. There are six main steps for using existing SRs <xref rid="b0035" ref-type="bibr">[7]</xref>, which can be applied to the vaccination field <xref rid="b0040" ref-type="bibr">[8]</xref> and are similar to frameworks leveraged in other health technology assessment areas <xref rid="b0045" ref-type="bibr">[9]</xref>.<list list-type="simple" id="l0020"><list-item id="o0020"><label>1)</label><p id="p0060">Defining PICO (Population, Intervention, Comparison, Outcome) elements,</p></list-item><list-item id="o0025"><label>2)</label><p id="p0065">locating existing SRs,</p></list-item><list-item id="o0030"><label>3)</label><p id="p0070">assessing their relevance and up-to-dateness,</p></list-item><list-item id="o0035"><label>4)</label><p id="p0075">assessing methodological quality and/or risk of bias,</p></list-item><list-item id="o0040"><label>5)</label><p id="p0080">determining appropriate use and incorporating the results of existing SRs, and</p></list-item><list-item id="o0045"><label>6)</label><p id="p0085">assessing applicability and transferability to local context</p></list-item></list></p>
    <p id="p0090">Each of the steps will be discussed in further detail below.</p>
    <sec id="s0025">
      <label>2.1</label>
      <title>Defining PICO (Population, Intervention, Comparison, Outcome) elements</title>
      <p id="p0095">The recommendation-making process usually starts with a broad policy question, which may be posed by a Ministry of Health and directed to the NITAG or developed by the NITAG itself <xref rid="b0050" ref-type="bibr">[10]</xref>. To facilitate the search, screening, and analysis of SRs, this broad policy question should be refined and structured to a specific one. Specific policy questions, around which NITAGs develop a vaccination recommendation should include a population, intervention (and comparison group), and outcome or goal of the recommendation (see <bold>Appendix A2</bold>). These elements are known as PICO (Population, Intervention, Comparison, Outcome) <xref rid="b0055" ref-type="bibr">[11]</xref>.</p>
      <p id="p0100">See <xref rid="t0005" ref-type="table">Table 1</xref> for examples of different types of policy questions. As can be seen with the PCV13 (pneumococcal conjugate vaccine) example, a broad policy question may be broken down into multiple specific policy questions to address different facets. A taxonomy of types of overlap in PICO criteria was developed <xref rid="b0060" ref-type="bibr">[12]</xref> to help authors map the PICO to different SRs on the same topic. The taxonomy of overlap can help NITAGs assess the relevance of their specific policy question to that of the existing SRs.<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Examples of broad policy questions, specific policy questions, and PICO elements.</p></caption><table frame="hsides" rules="groups"><thead><tr><th><bold>Broad policy question</bold></th><th><bold>Specific policy question (including population, intervention, and outcome or goal)</bold></th><th><bold><underline>P</underline></bold>opulation <bold><underline>I</underline></bold>ntervention <bold><underline>C</underline></bold>omparison <bold><underline>O</underline></bold>utcome (e.g. on benefits and harms of interventions)</th></tr></thead><tbody><tr><td>Should routine HPV vaccination of female adolescents be recommended?</td><td>Should routine HPV vaccination, with two doses of any HPV vaccine given at least 5 months apart, be recommended in 9- to 14-year-old girls to reduce HPV infections and HPV-associated cancers?</td><td>P: 9–14-year-old girls<break/>I: 2 doses of HPV vaccination<break/>C: No vaccination<break/>O: Efficacy/effectiveness against HPV infection, anogenital warts/condyloma, cervical, oropharyngeal, anal and vaginal/vulvar (pre)cancer</td></tr><tr><td>Should influenza vaccination be recommended for pregnant women?</td><td>Should a single dose of any influenza vaccine be recommended for pregnant women in the 2nd trimester to reduce influenza-related hospitalization during pregnancy?</td><td>P: Pregnant women in 2nd trimester<break/>I: Single dose of influenza vaccine<break/>C: No vaccination<break/>O: Efficacy/effectiveness against hospitalization, premature birth, acute respiratory, cardiopulmonary, pneumonia and influenza diseases</td></tr><tr><td>Should PCV13 be recommended for infants in routine immunization programs?</td><td><list list-type="simple" id="l0005"><list-item id="o0005"><label>a)</label><p id="p0005">Should three doses of PCV13 be administered routinely to immunocompetent infants aged &lt; 12 months to reduce the overall incidence of invasive pneumococcal disease?</p></list-item></list></td><td>P: Immunocompetent infants aged &lt; 12 months<break/>I: 3 doses of PCV13<break/>C: No vaccination<break/>O: Invasive pneumococcal disease</td></tr><tr><td/><td><list list-type="simple" id="l0010"><list-item id="o0010"><label>b)</label><p id="p0010">Given the risk of serious adverse events after vaccination, should immunocompetent infants &lt; 12 months of age receive any dose of PCV13 vaccine to induce protection against pneumococcal disease?</p></list-item></list></td><td>P: Immunocompetent infants aged &lt; 12 months<break/>I: Any dose of PCV13<break/>C: No vaccination<break/>O: Serious adverse events</td></tr><tr><td/><td><list list-type="simple" id="l0015"><list-item id="o0015"><label>c)</label><p id="p0015">Should immunocompetent infants &lt; 12 months of age be given three instead of four doses of PCV13 to reduce the number of severe pneumococcal diseases?</p></list-item></list></td><td>P: Immunocompetent infants aged &lt; 12 months<break/>I: 3 doses of PCV13<break/>C: 4 doses of PCV13<break/>O: Invasive pneumococcal disease, pneumococcal community-acquired pneumonia, hospitalizations due to pneumococcal disease, and deaths</td></tr></tbody></table><table-wrap-foot><fn><p>HPV: <italic>human papillomavirus</italic>; PCV: pneumococcal conjugate vaccine.</p></fn></table-wrap-foot></table-wrap></p>
    </sec>
    <sec id="s0030">
      <label>2.2</label>
      <title>Locating existing systematic reviews</title>
      <p id="p0105">When searching for existing SRs, NITAGs should take a systematic, transparent, and reproducible approach. Such an approach entails identifying databases to search, defining eligibility criteria, and reviewing search results.</p>
      <sec id="s0035">
        <label>2.2.1</label>
        <title>Identifying databases to search</title>
        <p id="p0110">To ensure a comprehensive search for SRs, it is recommended to search both databases that exclusively or mostly contain SRs and general bibliographic databases that include reviews among other publications <xref rid="b0035" ref-type="bibr">[7]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>. An empirical study identified that 99.2 % of SRs on health-related topics were found by searching MEDLINE, Epistemonikos, and reference checking <xref rid="b0070" ref-type="bibr">[14]</xref>.</p>
        <p id="p0115"><italic>The SYSVAC registry includes reviews from MEDLINE, Embase, and the Cochrane Database of Systematic Reviews. SYSVAC includes SRs, including living, umbrella, and, for COVID-19 related topics, rapid reviews</italic>. Thus, if NITAGs are searching for non-systematic reviews (e.g., narrative reviews) or primary studies in their vaccination recommendation process, their search of SYSVAC should be supplemented with other bibliographic databases, as well as the grey literature and reference checking. Refer to <bold>Appendix A2</bold> for details on relevant databases to search and on devising a search strategy.</p>
      </sec>
      <sec id="s0040">
        <label>2.2.2</label>
        <title>Defining eligibility criteria</title>
        <p id="p0120">Criteria for including or excluding SRs need to be pre-defined to provide the framework for reviewing the evidence. Inclusion criteria should include the PICO elements and other outcomes of interests (see <xref rid="t0010" ref-type="table">Table 2</xref>). There may be SRs that do not fit the NITAG’s PICO precisely but rather are narrower or broader in scope. For example, when reviewing evidence on the efficacy of influenza vaccination during pregnancy, there might be relevant information both in SRs involving only pregnant women and in SRs involving a broader population, such as healthy adults.<table-wrap position="float" id="t0010"><label>Table 2</label><caption><p>Example of eligibility criteria.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td><inline-graphic xlink:href="fx1.gif"/></td></tr></tbody></table></table-wrap></p>
        <p id="p0125">NITAGs should decide how to operationalize the concept of a ‘systematic review.’ For example, they may decide to include only Cochrane Reviews, generally viewed as gold standard, which are prepared and supervised by a Cochrane Review Group and updated to reflect the findings of new evidence <xref rid="b0075" ref-type="bibr">[15]</xref>. SRs included in the SYSVAC registry are determined to be systematic in nature if the reviews label themselves as SRs in the title or abstract of the paper or describe the following minimum eligibility criteria such as those used by Robinson and colleagues <xref rid="b0080" ref-type="bibr">[16]</xref>:<list list-type="simple" id="l0025"><list-item id="o0050"><label>1)</label><p id="p0130">Explicit and adequate search</p></list-item><list-item id="o0055"><label>2)</label><p id="p0135">Application of pre-specified eligibility criteria</p></list-item><list-item id="o0060"><label>3)</label><p id="p0140">Assessment of quality or risk of bias of included studies</p></list-item><list-item id="o0065"><label>4)</label><p id="p0145">Synthesis or attempted synthesis of results</p></list-item></list></p>
        <p id="p0150">An exclusion criterion to consider is industry sponsorship. Previous studies have reported that private industry-sponsored randomized controlled trials and SRs with <italic>meta</italic>-analysis are more likely to report intervention-favourable results compared to other sources of funding <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0090" ref-type="bibr">[18]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>. Industry funded groups may undertake advocacy, education and research activities that echo their sponsors’ interests. For these reasons, some NITAGs may not be comfortable basing policy decisions on SRs led by vaccine manufacturers due to potential sponsorship bias. It is advisable to determine whether industry sponsorship would preclude study eligibility <xref rid="b0100" ref-type="bibr">[20]</xref>.</p>
      </sec>
      <sec id="s0045">
        <label>2.2.3</label>
        <title>Reviewing search results and deciding how to proceed</title>
        <p id="p0155">Different procedures can be followed depending on whether no SR was found, only one SR was found or multiple SRs exist (see <xref rid="f0005" ref-type="fig">Fig. 1</xref>).<fig id="f0005"><label>Fig. 1</label><caption><p>Scenarios for proceeding after reviewing search results. ACIP: Advisory Committee on Immunization Practices (NITAG United States of America); AMSTAR 2: A Measurement Tool to Assess systematic Reviews 2; JCVI: Joint Committee on Vaccination and Immunization (NITAG United Kingdom); NACI: National Advisory Committee on Immunization (NITAG Canada); PROSPERO: International prospective register of systematic reviews; SR: systematic review; ROBIS: Risk Of Bias In Systematic reviews; STIKO: Ständige Impfkommission (NITAG Germany).</p></caption><graphic xlink:href="gr1"/></fig></p>
        <p id="p0160">In the event that multiple SRs appear in the list of search results, NITAGs can consider choosing just one SR to use based on its relevance, up-to-dateness, methodological quality and/or risk of bias, or comprehensiveness (see <xref rid="f0005" ref-type="fig">Fig. 1</xref>). In practice, this decision may be challenging, and rarely will the most relevant SR also be the most up-to-date, of highest quality, and most comprehensive. Thus, NITAGs should be prepared to consider which criteria are most pertinent to the country context and be aware that prioritizing one criterion may mean neglecting another. Decision rules can be created <italic>a priori</italic>, e.g., if there are multiple SRs of the same methodological quality and/or risk of bias, the SR including the most studies for the outcome of interest will be selected first, followed by the most recent SR.</p>
        <p id="p0165">Another option at this juncture is to retain multiple SRs and proceed with assessing their relevance and up-to-dateness (see <bold>2.3</bold>). NITAGs could later consider reviewing the results of all relevant, up-to-date SRs of sufficient quality informally or by conducting an overview of SRs <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>. This approach would be particularly appropriate in cases where several SRs address different components of the PICO (e.g., SRs on different outcomes or populations within the PICO).</p>
      </sec>
    </sec>
    <sec id="s0050">
      <label>2.3</label>
      <title>Assessing relevance and up-to-dateness</title>
      <p id="p0170">After locating SRs, it is important that NITAGs assess them for relevance and up-to-dateness, as the SR(s) informing a recommendation should be as closely relevant to the research question and as up-to-date as possible.</p>
      <p id="p0175"><underline>Relevance</underline> is the extent to which an existing SR matches the specific question, the context (e.g., setting, time frame), and/or study designs considered. <underline>Up-to-dateness</underline>, sometimes referred to as “currency,” is the extent to which a SR has been conducted recently enough to meet the needs of NITAGs. Mostly based on the available guidance for relevance <xref rid="b0035" ref-type="bibr">[7]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref> and up-to-dateness <xref rid="b0115" ref-type="bibr">[23]</xref>, <xref rid="f0010" ref-type="fig">Fig. 2</xref> outlines factors that may assist with this determination. <bold>Appendix A3</bold> contains a concrete example on how to assess the relevance and up-to-dateness of a SR related to vaccination.<fig id="f0010"><label>Fig. 2</label><caption><p>Aspects to consider when assessing relevance and up-to-dateness <xref rid="b0035" ref-type="bibr">[7]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0115" ref-type="bibr">[23]</xref>. SR: systematic review.</p></caption><graphic xlink:href="gr2"/></fig></p>
      <p id="p0180">Deciding whether a SR is “up-to-date” can be difficult, as it is a subjective decision dependent on knowledge of the field covered by the SR. Regardless of the criteria used to determine up-to-dateness, the methods section of the SR, specifically, the date of last literature search conducted for the SR or the date of the most recent primary study included in the SR plays a critical role in this assessment. These dates serve as reference points for the decision on whether new relevant studies, methods, or information have emerged. <italic>The SYSVAC registry highlights the date of last literature search for its indexed SRs.</italic></p>
      <p id="p0185">Detailed guidance on how to update SRs goes beyond the scope of this paper. However, it is worth pointing out that, regardless of the reason for updating the SR (see <bold>Appendix 4,</bold>
<xref rid="s0005" ref-type="sec">Figure S1</xref> for examples), each update should begin with a “protocol refresh,” or a review of the background, research question, inclusion criteria, and methods of the existing SR <xref rid="b0115" ref-type="bibr">[23]</xref>. This process will help updaters think through all the aspects of a SR which may need to be updated and plan their update accordingly. It will also help them document their process, which is important for future updating efforts and for transparency. Comparing the protocol of an update to that of an existing SR can provide clues as to why findings across the SRs might differ. Additional resources and guidance on updating SRs can be found elsewhere <xref rid="b0045" ref-type="bibr">[9]</xref>, <xref rid="b0115" ref-type="bibr">[23]</xref>, <xref rid="b0120" ref-type="bibr">[24]</xref>.</p>
      <sec id="s0055">
        <label>2.3.1</label>
        <title>Outcome of assessments of relevance and up-to-dateness</title>
        <p id="p0190">NITAGs might encounter different results when assessing the relevance and up-to-dateness of SRs. Potential scenarios of relevance and up-to-dateness are shown in <xref rid="f0015" ref-type="fig">Fig. 3</xref>. On the right-hand side of the figure, approaches for proceeding in a given situation are described.<fig id="f0015"><label>Fig. 3</label><caption><p>Scenarios for proceeding after assessing relevance and up-to-dateness. SR: systematic review.</p></caption><graphic xlink:href="gr3"/></fig></p>
      </sec>
    </sec>
    <sec id="s0060">
      <label>2.4</label>
      <title>Assessing methodological quality and/or risk of bias</title>
      <p id="p0195">SRs should be used as the basis for reviewing evidence in the vaccination recommendation process only if they meet certain quality or risk of bias ratings. This step explains the concepts of quality and risk of bias and ways of assessing them.</p>
      <sec id="s0065">
        <label>2.4.1</label>
        <title>Methodological quality, risk of bias, and systematic review reporting</title>
        <p id="p0200"><underline>Methodological quality</underline> refers to how well the SR is conducted according to established guidance (e.g., Cochrane Handbook for Systematic Reviews of Interventions <xref rid="b0135" ref-type="bibr">[27]</xref>, JBI Manual for Evidence Synthesis <xref rid="b0140" ref-type="bibr">[28]</xref>). SRs with low methodological quality have flaws that have an uncertain impact on review findings <xref rid="b0145" ref-type="bibr">[29]</xref>.</p>
        <p id="p0205"><underline>Risk of bias</underline> refers to the extent to which systematic flaws or limitations in the design, conduct, or analysis of a SR influence the results or conclusions <xref rid="b0150" ref-type="bibr">[30]</xref>. Methodological quality and risk of bias are usually inversely related, such that SRs of high methodological quality also generally have low risk of bias. Nonetheless, it is possible for a SR to have poor methodological quality and be at low risk of bias, e.g., if a SR reports and discusses all methodological shortcomings according to the assessment tool guidelines but still contain fatal flaws, such as an insufficiently comprehensive search strategy leading to missing information <xref rid="b0155" ref-type="bibr">[31]</xref>.</p>
        <p id="p0210"><underline>SR reporting</underline> refers to the extent to which authors of SRs clearly and adequately report their approach and findings in their published manuscript. Clear and comprehensive reporting is necessary for the assessment of methodological quality and risk of bias. Without it, assessors of SRs cannot reliably interpret the findings of the SR, understand its strengths and limitations, or compare it with other SRs. To improve reporting of SRs and <italic>meta</italic>-analyses and provide a transparent checklist which SR authors can use to report their methods and findings, guidelines like PRISMA (Peer Review of Electronic Search Strategies) <xref rid="b0125" ref-type="bibr">[25]</xref> and the MOOSE guide (meta-analyses Of Observational Studies in Epidemiology) <xref rid="b0130" ref-type="bibr">[26]</xref> have been developed. PRISMA focuses on SRs of studies evaluating the effects of health interventions, irrespective of the design of the included studies, while MOOSE focuses on SRs of non-randomized studies. Both may also be useful for critical appraisal of published SRs although it is not a quality assessment instrument to gauge the quality of a SR<xref rid="b0125" ref-type="bibr">[25]</xref>.</p>
      </sec>
      <sec id="s0070">
        <label>2.4.2</label>
        <title>Tools to assess methodological quality and/or risk of bias of systematic reviews</title>
        <p id="p0215">A commonly used tool to assess the methodological quality of a SR is AMSTAR 2 (A MeaSurement Tool to Assess systematic Reviews 2) <xref rid="b0145" ref-type="bibr">[29]</xref>. ROBIS (Risk Of Bias In Systematic reviews) aims to assess the risk of bias of a SR <xref rid="b0150" ref-type="bibr">[30]</xref>. Both tools are appropriate for appraising SRs of randomized and non-randomized studies and have significant overlap. However, they differ in some items, the time required to apply them to a SR (“scoring time”), and intended area(s) of focus (see <xref rid="t0015" ref-type="table">Table 3</xref>). For example, conflict of interest, which is increasingly relevant in the vaccine review literature, is assessed by AMSTAR 2 but not by the ROBIS tool. Therefore, NITAGs using ROBIS might consider assessing conflict of interest as an additional step (e.g., determine whether a SR was authored by vaccine industry employees). While AMSTAR 2 has a narrower focus on SRs on healthcare interventions <xref rid="b0160" ref-type="bibr">[32]</xref>, ROBIS was designed to address a wider variety of research questions, including interventions, diagnosis, prognosis, and etiology <xref rid="b0145" ref-type="bibr">[29]</xref>, <xref rid="b0150" ref-type="bibr">[30]</xref>.<table-wrap position="float" id="t0015"><label>Table 3</label><caption><p>Comparison of AMSTAR 2 and ROBIS.</p></caption><table frame="hsides" rules="groups"><thead><tr><th><bold>Name of tool</bold></th><th><bold>Concept measured</bold></th><th><bold>Areas of research</bold></th><th><bold>Number of items</bold></th><th><bold>Items unique to tool (and associated item number)</bold></th><th><bold>Type of overall rating(s)</bold></th><th><bold>Characteristics of users</bold></th><th><bold>Scoring time</bold> (from <xref rid="b0170" ref-type="bibr">[34]</xref>)</th></tr></thead><tbody><tr><td>AMSTAR 2 <xref rid="b0145" ref-type="bibr">[29]</xref></td><td>Methodological quality</td><td>SR of healthcare interventions</td><td>16 items</td><td>- List of excluded studies and justification for exclusion provided by authors (7)<break/>- Sources of funding of included studies reported (10)<break/>- Potential conflicts of interests reported (16)</td><td>Overall confidence in the results of the review (critically low/ low/moderate/high), based on assessments of critical domains, pre-determined by user (appraisers can alternatively use the critical domains suggested by the AMSTAR 2 developers)</td><td>Health professionals and policy makers. No advanced training in epidemiology required.</td><td>20 min ± 12 min*</td></tr><tr><td>ROBIS <xref rid="b0150" ref-type="bibr">[30]</xref></td><td>Risk of bias</td><td>SR of interventions, diagnosis, prognosis, and etiology</td><td>21 items – 4 key domains, each including 5–6 signaling questions and a field for concerns</td><td>- Review relevant to research question (Phase 1, optional)<break/>- Appropriate eligibility criteria for research question (1.2)<break/>- Appropriate restrictions on information sources (1.5)<break/>- Relevant study results collected for synthesis (3.3)<break/>- Data possibly missing from synthesis (4.1)<break/>- Adherence to protocol (4.2)</td><td>Risk of bias ratings assigned for each domain and overall (low/high/unclear)</td><td>Authors of overviews of SRs, guidance developers, reviewers who may want to assess risk of bias in their SR once it is complete or to minimize the risk of bias when planning review methods. Content and methodological expertise needed.</td><td>29 min ± 17 min*</td></tr></tbody></table><table-wrap-foot><fn id="sp0055"><p>AMSTAR 2: A MeaSurement Tool to Assess systematic Reviews 2; ROBIS: Risk Of Bias In Systematic reviews; SR: systematic review.</p></fn><fn id="sp0060"><p>*time to complete the assessment.</p></fn></table-wrap-foot></table-wrap></p>
        <p id="p0220">It is worth noting that AMSTAR 2 and ROBIS exhibit a few notable limitations <xref rid="b0155" ref-type="bibr">[31]</xref>. As both critical appraisal tools are largely based on expert opinion, much work is to be done to establish their reliability and validity. Furthermore, they depend on high reporting quality comprehensiveness. Assessments are based on how methods and results are reported in SRs, so if reporting quality comprehensiveness is low, neither AMSTAR 2 nor ROBIS can provide valid assessments. Neither tool can capture content-related flaws, as they cannot assess whether the research question under consideration is weak or irrelevant, or determine if there are any relevant studies missing or incorrect data extraction that can lead to large differences in pooled effect estimates in <italic>meta</italic>-analyses <xref rid="b0165" ref-type="bibr">[33]</xref>. Ideally, only a content expert should decide these issues.</p>
        <p id="p0225">A concrete example of how AMSTAR 2 can be applied to a SR related to vaccination is shown in <bold>Appendix A4</bold>, <xref rid="s0005" ref-type="sec">Table S5</xref>.</p>
        <p id="p0230">NITAGs relying on existing SRs could assess either the methodological quality or risk of bias of reviews, or both. The key point is that some sort of critical assessment is necessary, using a valid and reliable instrument. A study by Pieper and colleagues suggested that reliability was slightly higher for AMSTAR 2 that for ROBIS, yet there was a high correlation between both tools, suggesting validity <xref rid="b0155" ref-type="bibr">[31]</xref>. Regardless of the tool chosen, it is important that its use by NITAGs be piloted on a sample of SRs, particularly when multiple people will be assessing the quality and/or risk of bias of existing SRs independently and in duplicate <xref rid="b0155" ref-type="bibr">[31]</xref>. Pilot testing helps ensure that assessments are being performed consistently and increase inter-rater reliability <xref rid="b0175" ref-type="bibr">[35]</xref>. <italic>SYSVAC users could consider using the AMSTAR 2 assessments provided in the registry, which have been performed by trained SYSVAC staff.</italic></p>
      </sec>
      <sec id="s0075">
        <label>2.4.3</label>
        <title>Results of methodological quality and/or risk of bias assessment</title>
        <p id="p0235">Determining whether a SR’s quality assessment results are “good enough” for a NITAG to use the review in the recommendation-making process is a challenge. One approach is to decide on a cut-off result or range. For example, SRs with “moderate” or “high” overall quality ratings might be used, based on their performance along the seven critical domains in AMSTAR 2. If using ROBIS, SRs with a “low” overall risk of bias rating might be used.</p>
        <p id="p0240">Possible scenarios and corresponding approaches for proceeding in a given situation are described in <xref rid="f0020" ref-type="fig">Fig. 4</xref>.<fig id="f0020"><label>Fig. 4</label><caption><p>Scenarios on how to proceed based on methodological quality and/or risk of bias assessments. For conciseness, “methodological quality and/or risk of bias” will be referred to as “quality.” SR: systematic review.</p></caption><graphic xlink:href="gr4"/></fig></p>
      </sec>
    </sec>
    <sec id="s0080">
      <label>2.5</label>
      <title>Determining appropriate use and incorporating existing reviews</title>
      <p id="p0245">At this point in the process, NITAGs have either identified a single SR or multiple SRs to use in the evidence review process. These SRs should be relevant to the NITAG’s specific policy question, up-to-date, and of sufficient quality/risk of bias. The following section describes how NITAGs might determine which elements to incorporate into the evidence review process. While the focus is on the use of a single SR, some guidance and resources are provided in the event NITAGs wish to use multiple SRs.</p>
      <sec id="s0085">
        <label>2.5.1</label>
        <title>Considerations when using systematic review(s)</title>
        <p id="p0250">When using an existing relevant and up-to-date SR of sufficient quality, the following elements of the SR (see below) might be incorporated into the evidence review:<list list-type="simple" id="l0030"><list-item id="o0070"><label>1)</label><p id="p0255">Data extraction – to check for quality of data abstraction, or if taking a narrower scope than the existing SR</p></list-item><list-item id="o0075"><label>2)</label><p id="p0260">Study-level quality/risk of bias assessment – to check standard of quality appraisal, to contrast quality appraisal of different SRs, or if quality criteria different to that used in the SR, or if taking a narrower scope</p></list-item><list-item id="o0080"><label>3)</label><p id="p0265">Synthesis – to combine and evaluate the extracted data to determine the outcomes of the existing SR</p></list-item></list></p>
        <p id="p0270">
          <italic>
            <underline>When using a single systematic review</underline>
          </italic>
          <list list-type="simple" id="l0035">
            <list-item id="o0085">
              <label>(1)</label>
              <p id="p0275">Data extraction</p>
            </list-item>
          </list>
        </p>
        <p id="p0280">Data extraction tables of existing SR should be examined carefully to determine if they meet respective needs and quality standards. For example, only tables where at least two reviewers performed data extraction and where results of individual trials are reported should be used. Any missing information across the SR should be extracted from the original included primary studies or contacting the authors of the SR or authors of the included studies <xref rid="b0035" ref-type="bibr">[7]</xref>. The data extracted by authors of the existing SR and data gleaned from SR or authors of included studies should be clearly distinguished, e.g., by using separate tables. If primary studies will be included in the evidence review that are not already in the existing SR, they need to be distinguished as well <xref rid="b0080" ref-type="bibr">[16]</xref>.<list list-type="simple" id="l0040"><list-item id="o0090"><label>(2)</label><p id="p0285">Study-level quality/risk of bias assessment</p></list-item></list></p>
        <p id="p0290">Primary studies for all relevant outcomes should be assessed for quality/risk of bias. When deciding whether to use existing quality assessments, consider the following points:<list list-type="simple" id="l0045"><list-item id="o0095"><label>•</label><p id="p0295">Have the authors of existing SR reported their process of critically appraising included studies clearly and was an accepted and up-to-date critical appraisal tool used (e.g., ROBINS-I for non-randomized studies of interventions <xref rid="b0160" ref-type="bibr">[32]</xref>, RoB 2 for randomized controlled trials (Risk of Bias 2) <xref rid="b0180" ref-type="bibr">[36]</xref>)?</p></list-item><list-item id="o0100"><label>•</label><p id="p0300">If including primary studies in the evidence review in addition to those in the existing SR, is the critical appraisal tool used in the existing SR similar to the tool used for the other primary studies and performed similarly?</p></list-item></list></p>
        <p id="p0305">If the conditions to any of the above points or questions are not met, consider not using existing assessments and instead redo the quality/risk of bias assessment, using an accepted tool of choice.<list list-type="simple" id="l0050"><list-item id="o0105"><label>(3)</label><p id="p0310">Synthesis</p></list-item></list></p>
        <p id="p0315">The results of a single SR should be integrated if its methods are in line with those used by the NITAG or NITAG Secretariat for finding evidence, assessing quality of included studies, and grading the strength of evidence. If primary studies are included in the evidence review in addition to those in the existing SR, distinguish them, both narratively and in tables.</p>
        <p id="p0320">
          <italic>
            <underline>When using multiple systematic reviews</underline>
          </italic>
        </p>
        <p id="p0325">When facing multiple relevant, up-to-date, high-quality existing SRs addressing the immunization policy question, either the results of all can be reviewed informally or an overview of SRs can be conducted. An overview of SRs synthesizes evidence from multiple SRs. It may investigate the same intervention for different conditions, problems, or populations; multiple outcomes of the same intervention for the same condition or population; or adverse effects from a single intervention or class of related interventions for one or more conditions <xref rid="b0185" ref-type="bibr">[37]</xref>. While overviews of reviews resemble SRs in the use of systematic, transparent, and reproducible methods, a key distinction is that their unit of searching, inclusion, and analysis is SRs, as opposed to primary studies <xref rid="b0190" ref-type="bibr">[38]</xref>. Further information on conducting overviews of SRs can be found in the literature <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>.</p>
        <p id="p0330">However, general considerations when facing multiple SRs are mentioned below. The focus is on the use of existing data abstraction, study-level quality/risk of bias assessments, and syntheses since these elements are likely to be the most relevant when integrating multiple SRs in an evidence review.<list list-type="simple" id="l0055"><list-item id="o0110"><label>(1)</label><p id="p0335">Data extraction</p></list-item></list></p>
        <p id="p0340">Consider the same points as for the use of data extraction tables from a single SR (see above).<list list-type="simple" id="l0060"><list-item id="o0115"><label>(2)</label><p id="p0345">Study-level quality/risk of bias assessment</p></list-item></list></p>
        <p id="p0350">When deciding whether to use existing quality assessments, consider the same points as for the use of an existing quality assessment from a single SR (see above), in addition to the following questions:<list list-type="simple" id="l0065"><list-item id="o0120"><label>•</label><p id="p0355">Did existing SRs use the same tool for critical assessment?</p></list-item><list-item id="o0125"><label>•</label><p id="p0360">Were quality/risk of bias assessments performed consistently and correctly across existing SRs? NITAGs can assess this by quality-checking a sample of studies across the SRs and/or extracting all quality/risk of bias assessment data, comparing them across SRs, and recording discrepancies <xref rid="b0110" ref-type="bibr">[22]</xref>. Any missing information necessary for assessing the studies or for reconciling discrepancies across assessments can be added by referring to included studies or contacting the authors of the reviews or authors of the included studies.</p></list-item></list></p>
        <p id="p0365">Quality/risk of bias assessments should be added if missing for any of the SRs. Redoing quality/risk of bias assessments for individual studies across multiple SRs can result in significant amount of work and expenses, if the NITAG does not have access to the full text of studies. The feasibility of such an undertaking should be considered. <italic>The SYSVAC registry informs users about whether or not the SRs included in the registry are available as open access.</italic><list list-type="simple" id="l0070"><list-item id="o0130"><label>(3)</label><p id="p0370">Synthesis</p></list-item></list></p>
        <p id="p0375">When integrating the results of multiple SRs, it is important to describe each SR, including findings, number and types of included studies, number of study population, and point estimates of effect measures and their confidence intervals <xref rid="b0080" ref-type="bibr">[16]</xref>. These elements can generally be taken from the SRs, although quality checks should be performed to ensure that one agrees with how the SR authors synthesized their data and to prevent errors in data extraction. New analyses may be necessary if the SRs analyze different populations or subgroups <xref rid="b0035" ref-type="bibr">[7]</xref>, if existing SRs are to be supplemented with new primary studies or with new or different <italic>meta</italic>-analytic methods, or if the results of the existing SRs are not trustworthy <xref rid="b0110" ref-type="bibr">[22]</xref>.</p>
        <p id="p0380">An overlap (or lack of overlap) in included primary studies across the SRs should be shown visually <xref rid="b0195" ref-type="bibr">[39]</xref>, <xref rid="b0200" ref-type="bibr">[40]</xref>. This can be done by using a matrix like in <xref rid="t0020" ref-type="table">Table 4</xref> below, where the grey boxes represent the primary studies in each SR. By scanning the rows, it becomes visible which of the studies are included in all SRs. Alternatively, to facilitate the assessment of overlap of primary studies among SRs, free tools like GROOVE (Graphical Representation of Overlap for OVErviews) <xref rid="b0205" ref-type="bibr">[41]</xref> might be used.<table-wrap position="float" id="t0020"><label>Table 4</label><caption><p>Sample matrix to present overlapping studies across systematic reviews.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td><inline-graphic xlink:href="fx2.gif"/></td></tr></tbody></table><table-wrap-foot><fn><p>Grey boxes represent the primary studies in each systematic review.</p></fn></table-wrap-foot></table-wrap></p>
        <p id="p0385">A common challenge in synthesizing multiple existing SRs is that they may reach different results and/or conclusions, based on different PICO, methodological decisions, judgments, or interpretations made by the authors <xref rid="b0210" ref-type="bibr">[42]</xref>, <xref rid="b0215" ref-type="bibr">[43]</xref>. To address this challenge, the following non-mutually-exclusive approaches should be considered:<list list-type="simple" id="l0075"><list-item id="o0135"><label>1)</label><p id="p0390">Determine reasons for the discordance and discuss these in the report <xref rid="b0035" ref-type="bibr">[7]</xref>.</p></list-item><list-item id="o0140"><label>2)</label><p id="p0395">Present the discordance in a table or graphic <xref rid="b0110" ref-type="bibr">[22]</xref>.</p></list-item><list-item id="o0145"><label>3)</label><p id="p0400">Use a decision rule, which summarizes the process for identifying and resolving causes of discordance, like the Jadad algorithm <xref rid="b0210" ref-type="bibr">[42]</xref>, to select just one SR.</p></list-item></list></p>
      </sec>
    </sec>
    <sec id="s0090">
      <label>2.6</label>
      <title>Assessing applicability and transferability</title>
      <p id="p0405">The following section provides initial considerations regarding the applicability and transferability of evidence from identified SRs to a specific setting for which a vaccination recommendation will be developed.</p>
      <p id="p0410"><underline>Applicability</underline> is the extent to which an intervention can be implemented in a new setting or how feasible it is to implement an intervention elsewhere <xref rid="b0220" ref-type="bibr">[44]</xref>. <underline>Transferability</underline> is the extent to which the effectiveness of an intervention achieved in one setting can be achieved in another <xref rid="b0220" ref-type="bibr">[44]</xref>. Both concepts are important to consider in evidence-based decision making, given the context-specific nature of public health interventions. An intervention that was effective in one setting might be ineffective in another, due to contextual factors.</p>
      <sec id="s0095">
        <label>2.6.1</label>
        <title>Checklist of contextual factors</title>
        <p id="p0415"><xref rid="t0025" ref-type="table">Table 5</xref> offers a preliminary list of contextual factors to consider when thinking about how evidence from SRs might work in a specific population or setting. To identify characteristics stratifying health opportunities and outcomes, consider using the PROGRESS-Plus framework (Place of residence, Race/ethnicity/culture/language, Occupation, Gender/sex, Religion, Education, Socioeconomic status, Social capital) <xref rid="b0225" ref-type="bibr">[45]</xref>, <xref rid="b0230" ref-type="bibr">[46]</xref>, <xref rid="b0235" ref-type="bibr">[47]</xref> and other factors adapted to the vaccine context <xref rid="b0240" ref-type="bibr">[48]</xref>, <xref rid="b0245" ref-type="bibr">[49]</xref>. Not all of these factors will be relevant to every SR that is being used by NITAGs and may be the optimal method for applicability assessments <xref rid="b0250" ref-type="bibr">[50]</xref>. Decision-makers might prioritize these factors in different ways.<table-wrap position="float" id="t0025"><label>Table 5</label><caption><p>Checklist of contextual factors to consider how evidence from systematic reviews might work in a specific population or setting.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="3"><bold>Setting and population</bold><break/>Consider the setting and population for which you are developing vaccination recommendations.<break/></td><td>• How similar is your setting to the settings of the individual studies included in the SR? Consider the available financial and human resources and existing services, policies, and programs.</td></tr><tr><td>• How similar is your population to the study population? Consider, e.g., sociodemographic profile, beliefs, values, immunological conditions, host genetics, use of medications, prior exposure to or vaccination against similar viruses, likelihood of coinfection with other pathogens, geographic factors, epidemiological factors (including local burden of disease), literacy, and maternal health/breastfeeding context (i.e., to assess exposure to maternal antibodies and antigens in breastmilk). Also consider the heterogeneity/homogeneity of the study populations compared to your population.</td></tr><tr><td>• How easily could the intervention be implemented in your setting? Consider potential facilitators and barriers. These may be related to the availability of resources, skills of local staff, organizational factors, and social and political environment (e.g., acceptability, political will).</td></tr><tr><td rowspan="5"><bold>Intervention</bold><break/>Consider the intervention examined in the SR and compare it to what is locally available or are considered locally.<break/></td><td>• What were the intervention components (e.g., vaccine, vaccine components)?</td></tr><tr><td>• Who delivered the intervention?</td></tr><tr><td>• How was the intervention implemented (e.g., dose schedule)?</td></tr><tr><td>• What resources (e.g., financial, human, equipment) were required to deliver the intervention?</td></tr><tr><td>• Was the intervention delivered as intended? Was it adapted or modified over time?</td></tr><tr><td rowspan="2"><bold>Outcomes</bold><break/>Consider the outcomes examined in the SR and compare them to outcomes relevant to your context.<break/></td><td>• What unintended effects or adverse events were reported? Did these vary by population subgroup or intervention approach?</td></tr><tr><td>• What diagnostic tests (e.g., assay) were used?</td></tr></tbody></table><table-wrap-foot><fn><p>SR: systematic review.</p></fn></table-wrap-foot></table-wrap></p>
      </sec>
    </sec>
  </sec>
  <sec id="s0100">
    <label>3</label>
    <title>Conclusions</title>
    <p id="p0420">In practice, it will not always be easy to identify existing SRs that match a decision-maker’s research question or to select one SR from among multiple SRs. Relevance, up-to-dateness, methodological quality and/or risk of bias, and comprehensiveness are all important criteria, and rarely will the most relevant SR also be the most up-to-date, of highest quality, and most comprehensive. Thus, NITAGs should be prepared to reconsider key criteria and make tradeoffs when using SRs for the development of vaccination recommendations.</p>
    <p id="p0425">Additional tools that may assist NITAGs in using SRs are the e-learning course and SYSVAC registry, which are both freely accessible at <ext-link ext-link-type="uri" xlink:href="https://www.nitag-resource.org/sysvac-systematic-reviews" id="ir015">https://www.nitag-resource.org/sysvac-systematic-reviews</ext-link>.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Declaration of Competing Interest</title>
    <p id="p0430">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p>
  </sec>
</body>
<back>
  <ref-list id="bi005">
    <title>References</title>
    <ref id="b0005">
      <label>1</label>
      <element-citation publication-type="journal" id="h0005">
        <person-group person-group-type="author">
          <name>
            <surname>Duclos</surname>
            <given-names>P.</given-names>
          </name>
        </person-group>
        <article-title>National Immunization Technical Advisory Groups (NITAGs): guidance for their establishment and strengthening</article-title>
        <source>Vaccine</source>
        <volume>28</volume>
        <issue>Suppl 1</issue>
        <year>2010</year>
        <fpage>A18</fpage>
        <lpage>A25</lpage>
        <pub-id pub-id-type="doi">10.1016/j.vaccine.2010.02.027</pub-id>
        <pub-id pub-id-type="pmid">20412991</pub-id>
      </element-citation>
    </ref>
    <ref id="b0010">
      <label>2</label>
      <element-citation publication-type="journal" id="h0010">
        <person-group person-group-type="author">
          <name>
            <surname>Bero</surname>
            <given-names>L.A.</given-names>
          </name>
          <name>
            <surname>Jadad</surname>
            <given-names>A.R.</given-names>
          </name>
        </person-group>
        <article-title>How Consumers and Policymakers Can Use Systematic Reviews for Decision Making</article-title>
        <source>Ann Intern Med</source>
        <volume>127</volume>
        <issue>1</issue>
        <year>1997</year>
        <fpage>37</fpage>
        <lpage>42</lpage>
        <pub-id pub-id-type="doi">10.7326/0003-4819-127-1-199707010-00007</pub-id>
        <pub-id pub-id-type="pmid">9214251</pub-id>
      </element-citation>
    </ref>
    <ref id="b0015">
      <label>3</label>
      <element-citation publication-type="journal" id="h0015">
        <person-group person-group-type="author">
          <name>
            <surname>Lavis</surname>
            <given-names>J.N.</given-names>
          </name>
          <name>
            <surname>Posada</surname>
            <given-names>F.B.</given-names>
          </name>
          <name>
            <surname>Haines</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Osei</surname>
            <given-names>E.</given-names>
          </name>
        </person-group>
        <article-title>Use of research to inform public policymaking</article-title>
        <source>Lancet</source>
        <volume>364</volume>
        <issue>9445</issue>
        <year>2004</year>
        <fpage>1615</fpage>
        <lpage>1621</lpage>
        <pub-id pub-id-type="doi">10.1016/S0140-6736(04)17317-0</pub-id>
        <pub-id pub-id-type="pmid">15519634</pub-id>
      </element-citation>
    </ref>
    <ref id="b0020">
      <label>4</label>
      <element-citation publication-type="journal" id="h0020">
        <person-group person-group-type="author">
          <name>
            <surname>Moat</surname>
            <given-names>K.A.</given-names>
          </name>
          <name>
            <surname>Lavis</surname>
            <given-names>J.N.</given-names>
          </name>
          <name>
            <surname>Wilson</surname>
            <given-names>M.G.</given-names>
          </name>
          <name>
            <surname>Rottingen</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Barnighausen</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Twelve myths about systematic reviews for health system policymaking rebutted</article-title>
        <source>J Health Serv Res Policy</source>
        <volume>18</volume>
        <issue>1</issue>
        <year>2013</year>
        <fpage>44</fpage>
        <lpage>50</lpage>
        <pub-id pub-id-type="doi">10.1258/jhsrp.2012.011175</pub-id>
        <pub-id pub-id-type="pmid">23393042</pub-id>
      </element-citation>
    </ref>
    <ref id="b0025">
      <label>5</label>
      <element-citation publication-type="journal" id="h0025">
        <person-group person-group-type="author">
          <name>
            <surname>Fernandes</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Jit</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Bozzani</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Griffiths</surname>
            <given-names>U.K.</given-names>
          </name>
          <name>
            <surname>Scott</surname>
            <given-names>J.A.G.</given-names>
          </name>
          <name>
            <surname>Burchett</surname>
            <given-names>H.E.D.</given-names>
          </name>
        </person-group>
        <article-title>A bibliometric analysis of systematic reviews on vaccines and immunisation</article-title>
        <source>Vaccine</source>
        <volume>36</volume>
        <issue>17</issue>
        <year>2018</year>
        <fpage>2254</fpage>
        <lpage>2261</lpage>
        <pub-id pub-id-type="doi">10.1016/j.vaccine.2018.02.049</pub-id>
        <pub-id pub-id-type="pmid">29576305</pub-id>
      </element-citation>
    </ref>
    <ref id="b0030">
      <label>6</label>
      <element-citation publication-type="journal" id="h0030">
        <person-group person-group-type="author">
          <name>
            <surname>Jo</surname>
            <given-names>C.L.</given-names>
          </name>
          <name>
            <surname>Burchett</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Bastias</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Campbell</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Gamage</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Henaff</surname>
            <given-names>L.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Using existing systematic reviews for developing vaccination recommendations: Results of an international expert workshop</article-title>
        <source>Vaccine</source>
        <volume>39</volume>
        <issue>23</issue>
        <year>2021</year>
        <fpage>3103</fpage>
        <lpage>3110</lpage>
        <pub-id pub-id-type="doi">10.1016/j.vaccine.2021.04.045</pub-id>
        <pub-id pub-id-type="pmid">33965256</pub-id>
      </element-citation>
    </ref>
    <ref id="b0035">
      <label>7</label>
      <element-citation publication-type="journal" id="h0035">
        <person-group person-group-type="author">
          <name>
            <surname>Robinson</surname>
            <given-names>K.A.</given-names>
          </name>
          <name>
            <surname>Whitlock</surname>
            <given-names>E.P.</given-names>
          </name>
          <name>
            <surname>Oneil</surname>
            <given-names>M.E.</given-names>
          </name>
          <name>
            <surname>Anderson</surname>
            <given-names>J.K.</given-names>
          </name>
          <name>
            <surname>Hartling</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Dryden</surname>
            <given-names>D.M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integration of existing systematic reviews into new reviews: identification of guidance needs</article-title>
        <source>Syst Rev</source>
        <volume>3</volume>
        <year>2014</year>
        <fpage>60</fpage>
        <pub-id pub-id-type="doi">10.1186/2046-4053-3-60</pub-id>
        <pub-id pub-id-type="pmid">24956937</pub-id>
      </element-citation>
    </ref>
    <ref id="b0040">
      <label>8</label>
      <element-citation publication-type="journal" id="h0040">
        <person-group person-group-type="author">
          <name>
            <surname>Harder</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Remschmidt</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Haller</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Eckmanns</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Wichmann</surname>
            <given-names>O.</given-names>
          </name>
        </person-group>
        <article-title>Use of existing systematic reviews for evidence assessments in infectious disease prevention: a comparative case study</article-title>
        <source>Syst Rev</source>
        <volume>5</volume>
        <issue>1</issue>
        <year>2016</year>
        <fpage>171</fpage>
        <pub-id pub-id-type="doi">10.1186/s13643-016-0347-9</pub-id>
        <pub-id pub-id-type="pmid">27724950</pub-id>
      </element-citation>
    </ref>
    <ref id="b0045">
      <label>9</label>
      <element-citation publication-type="journal" id="h0045">
        <person-group person-group-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>J.S.M.</given-names>
          </name>
          <name>
            <surname>Pollock</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Kaunelis</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Weeks</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>Guidance on review type selection for health technology assessments: key factors and considerations for deciding when to conduct a de novo systematic review, an update of a systematic review, or an overview of systematic reviews</article-title>
        <source>Syst Rev</source>
        <volume>11</volume>
        <issue>1</issue>
        <year>2022</year>
        <fpage>206</fpage>
        <pub-id pub-id-type="doi">10.1186/s13643-022-02071-7</pub-id>
        <pub-id pub-id-type="pmid">36167611</pub-id>
      </element-citation>
    </ref>
    <ref id="b0050">
      <label>10</label>
      <mixed-citation publication-type="other" id="h0050">World Health Organization, Europe ROf. Guidance on an adapted evidence to recommendation process for National Immunization Technical Advisory Groups. World Health Organization. Regional Office for Europe, 2022 Contract No.: WHO/EURO: 2022-5497-45262-64756.</mixed-citation>
    </ref>
    <ref id="b0055">
      <label>11</label>
      <mixed-citation publication-type="other" id="h0055">Thomas J, Kneale D, McKenzie JE, Brennan SE, Bhaumik S. Chapter 2: Determining the scope of the review and the questions it will address. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from wwwtrainingcochraneorg/handbook. 2022.</mixed-citation>
    </ref>
    <ref id="b0060">
      <label>12</label>
      <element-citation publication-type="journal" id="h0060">
        <person-group person-group-type="author">
          <name>
            <surname>Lunny</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Reid</surname>
            <given-names>E.K.</given-names>
          </name>
          <name>
            <surname>Neelakant</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>J.H.</given-names>
          </name>
          <name>
            <surname>Shinger</surname>
            <given-names>G.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A new taxonomy was developed for overlap across 'overviews of systematic reviews': A meta-research study of research waste</article-title>
        <source>Res Synth Methods</source>
        <volume>13</volume>
        <issue>3</issue>
        <year>2022</year>
        <fpage>315</fpage>
        <lpage>329</lpage>
        <pub-id pub-id-type="doi">10.1002/jrsm.1542</pub-id>
        <pub-id pub-id-type="pmid">34927388</pub-id>
      </element-citation>
    </ref>
    <ref id="b0065">
      <label>13</label>
      <element-citation publication-type="journal" id="h0065">
        <person-group person-group-type="author">
          <name>
            <surname>Lunny</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Brennan</surname>
            <given-names>S.E.</given-names>
          </name>
          <name>
            <surname>McDonald</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>McKenzie</surname>
            <given-names>J.E.</given-names>
          </name>
        </person-group>
        <article-title>Toward a comprehensive evidence map of overview of systematic review methods: paper 1-purpose, eligibility, search and data extraction</article-title>
        <source>Syst Rev</source>
        <volume>6</volume>
        <issue>1</issue>
        <year>2017</year>
        <fpage>231</fpage>
        <pub-id pub-id-type="doi">10.1186/s13643-017-0617-1</pub-id>
        <pub-id pub-id-type="pmid">29162130</pub-id>
      </element-citation>
    </ref>
    <ref id="b0070">
      <label>14</label>
      <element-citation publication-type="journal" id="h0070">
        <person-group person-group-type="author">
          <name>
            <surname>Goossen</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Hess</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Lunny</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Pieper</surname>
            <given-names>D.</given-names>
          </name>
        </person-group>
        <article-title>Database combinations to retrieve systematic reviews in overviews of reviews: a methodological study</article-title>
        <source>BMC Med Res Method</source>
        <volume>20</volume>
        <issue>1</issue>
        <year>2020</year>
        <fpage>138</fpage>
        <pub-id pub-id-type="doi">10.1186/s12874-020-00983-3</pub-id>
      </element-citation>
    </ref>
    <ref id="b0075">
      <label>15</label>
      <mixed-citation publication-type="other" id="h0075">Library C. Cochrane Database of Systematic Reviews 2022. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.cochranelibrary.com/cdsr/about-cdsr" id="ir025">https://www.cochranelibrary.com/cdsr/about-cdsr</ext-link>.</mixed-citation>
    </ref>
    <ref id="b0080">
      <label>16</label>
      <element-citation publication-type="journal" id="h0080">
        <person-group person-group-type="author">
          <name>
            <surname>Robinson</surname>
            <given-names>K.A.</given-names>
          </name>
          <name>
            <surname>Chou</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Berkman</surname>
            <given-names>N.D.</given-names>
          </name>
          <name>
            <surname>Newberry</surname>
            <given-names>S.J.</given-names>
          </name>
          <name>
            <surname>Fu</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Hartling</surname>
            <given-names>L.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Twelve recommendations for integrating existing systematic reviews into new reviews: EPC guidance</article-title>
        <source>J Clin Epidemiol</source>
        <volume>70</volume>
        <year>2016</year>
        <fpage>38</fpage>
        <lpage>44</lpage>
        <pub-id pub-id-type="doi">10.1016/j.jclinepi.2015.05.035</pub-id>
        <pub-id pub-id-type="pmid">26261004</pub-id>
      </element-citation>
    </ref>
    <ref id="b0085">
      <label>17</label>
      <element-citation publication-type="journal" id="h0085">
        <person-group person-group-type="author">
          <name>
            <surname>Lexchin</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Bero</surname>
            <given-names>L.A.</given-names>
          </name>
          <name>
            <surname>Djulbegovic</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Clark</surname>
            <given-names>O.</given-names>
          </name>
        </person-group>
        <article-title>Pharmaceutical industry sponsorship and research outcome and quality: systematic review</article-title>
        <source>BMJ</source>
        <volume>326</volume>
        <issue>7400</issue>
        <year>2003</year>
        <fpage>1167</fpage>
        <lpage>1170</lpage>
        <pub-id pub-id-type="doi">10.1136/bmj.326.7400.1167</pub-id>
        <pub-id pub-id-type="pmid">12775614</pub-id>
      </element-citation>
    </ref>
    <ref id="b0090">
      <label>18</label>
      <element-citation publication-type="journal" id="h0090">
        <person-group person-group-type="author">
          <name>
            <surname>Lundh</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Lexchin</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Mintzes</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Schroll</surname>
            <given-names>J.B.</given-names>
          </name>
          <name>
            <surname>Bero</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>Industry sponsorship and research outcome</article-title>
        <source>Cochrane Database Syst Rev</source>
        <year>2017</year>
        <fpage>(2)</fpage>
        <pub-id pub-id-type="doi">10.1002/14651858.MR000033.pub3</pub-id>
      </element-citation>
    </ref>
    <ref id="b0095">
      <label>19</label>
      <element-citation publication-type="journal" id="h0095">
        <person-group person-group-type="author">
          <name>
            <surname>Bekelman</surname>
            <given-names>J.E.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Gross</surname>
            <given-names>C.P.</given-names>
          </name>
        </person-group>
        <article-title>Scope and impact of financial conflicts of interest in biomedical research: a systematic review</article-title>
        <source>JAMA</source>
        <volume>289</volume>
        <issue>4</issue>
        <year>2003</year>
        <fpage>454</fpage>
        <lpage>465</lpage>
        <pub-id pub-id-type="doi">10.1001/jama.289.4.454</pub-id>
        <pub-id pub-id-type="pmid">12533125</pub-id>
      </element-citation>
    </ref>
    <ref id="b0100">
      <label>20</label>
      <element-citation publication-type="journal" id="h0100">
        <person-group person-group-type="author">
          <name>
            <surname>Pieper</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Hellbrecht</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Baur</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Pick</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Schneider</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Impact of industry sponsorship on the quality of systematic reviews of vaccines: a cross-sectional analysis of studies published from 2016 to 2019</article-title>
        <source>Syst Rev</source>
        <volume>11</volume>
        <issue>1</issue>
        <year>2022</year>
        <fpage>174</fpage>
        <pub-id pub-id-type="doi">10.1186/s13643-022-02051-x</pub-id>
        <pub-id pub-id-type="pmid">35996186</pub-id>
      </element-citation>
    </ref>
    <ref id="b0105">
      <label>21</label>
      <mixed-citation publication-type="other" id="h0105">Training C. Overviews of reviews 2014. Available from: <ext-link ext-link-type="uri" xlink:href="https://training.cochrane.org/resource/overviews-reviews" id="ir030">https://training.cochrane.org/resource/overviews-reviews</ext-link>.</mixed-citation>
    </ref>
    <ref id="b0110">
      <label>22</label>
      <element-citation publication-type="journal" id="h0110">
        <person-group person-group-type="author">
          <name>
            <surname>Lunny</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Brennan</surname>
            <given-names>S.E.</given-names>
          </name>
          <name>
            <surname>McDonald</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>McKenzie</surname>
            <given-names>J.E.</given-names>
          </name>
        </person-group>
        <article-title>Toward a comprehensive evidence map of overview of systematic review methods: paper 2-risk of bias assessment; synthesis, presentation and summary of the findings; and assessment of the certainty of the evidence</article-title>
        <source>Syst Rev</source>
        <volume>7</volume>
        <issue>1</issue>
        <year>2018</year>
        <fpage>159</fpage>
        <pub-id pub-id-type="doi">10.1186/s13643-018-0784-8</pub-id>
        <pub-id pub-id-type="pmid">30314530</pub-id>
      </element-citation>
    </ref>
    <ref id="b0115">
      <label>23</label>
      <element-citation publication-type="journal" id="h0115">
        <person-group person-group-type="author">
          <name>
            <surname>Garner</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Hopewell</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Chandler</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>MacLehose</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Akl</surname>
            <given-names>E.A.</given-names>
          </name>
          <name>
            <surname>Beyene</surname>
            <given-names>J.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>When and how to update systematic reviews: consensus and checklist</article-title>
        <source>BMJ</source>
        <volume>354</volume>
        <year>2016</year>
        <object-id pub-id-type="publisher-id">i3507</object-id>
        <pub-id pub-id-type="doi">10.1136/bmj.i3507</pub-id>
      </element-citation>
    </ref>
    <ref id="b0120">
      <label>24</label>
      <mixed-citation publication-type="other" id="h0120">Cumpston M, Chandler J. Chapter IV: Updating a review. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane Handbook for Systematic Reviews of Interventions version 60 (updated August 2019): Cochrane; 2019.</mixed-citation>
    </ref>
    <ref id="b0125">
      <label>25</label>
      <element-citation publication-type="journal" id="h0125">
        <person-group person-group-type="author">
          <name>
            <surname>Page</surname>
            <given-names>M.J.</given-names>
          </name>
          <name>
            <surname>McKenzie</surname>
            <given-names>J.E.</given-names>
          </name>
          <name>
            <surname>Bossuyt</surname>
            <given-names>P.M.</given-names>
          </name>
          <name>
            <surname>Boutron</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Hoffmann</surname>
            <given-names>T.C.</given-names>
          </name>
          <name>
            <surname>Mulrow</surname>
            <given-names>C.D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title>
        <source>BMJ</source>
        <volume>372</volume>
        <year>2021</year>
        <object-id pub-id-type="publisher-id">n71</object-id>
        <pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id>
      </element-citation>
    </ref>
    <ref id="b0130">
      <label>26</label>
      <element-citation publication-type="journal" id="h0130">
        <person-group person-group-type="author">
          <name>
            <surname>Stroup</surname>
            <given-names>D.F.</given-names>
          </name>
          <name>
            <surname>Berlin</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Morton</surname>
            <given-names>S.C.</given-names>
          </name>
          <name>
            <surname>Olkin</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Williamson</surname>
            <given-names>G.D.</given-names>
          </name>
          <name>
            <surname>Rennie</surname>
            <given-names>D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group</article-title>
        <source>JAMA</source>
        <volume>283</volume>
        <issue>15</issue>
        <year>2000</year>
        <fpage>2008</fpage>
        <lpage>2012</lpage>
        <pub-id pub-id-type="doi">10.1001/jama.283.15.2008</pub-id>
        <pub-id pub-id-type="pmid">10789670</pub-id>
      </element-citation>
    </ref>
    <ref id="b0135">
      <label>27</label>
      <mixed-citation publication-type="other" id="h0135">Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane Available from wwwtrainingcochraneorg/handbook. 2022.</mixed-citation>
    </ref>
    <ref id="b0140">
      <label>28</label>
      <mixed-citation publication-type="other" id="h0140">Aromataris E, Munn Z. JBI Manual for Evidence Synthesis. JBI Available from <ext-link ext-link-type="uri" xlink:href="https://synthesismanualjbiglobal" id="ir035">https://synthesismanualjbiglobal</ext-link>. 2020. doi: https://doi.org/10.46658/JBIMES-20-01.</mixed-citation>
    </ref>
    <ref id="b0145">
      <label>29</label>
      <element-citation publication-type="journal" id="h0145">
        <person-group person-group-type="author">
          <name>
            <surname>Shea</surname>
            <given-names>B.J.</given-names>
          </name>
          <name>
            <surname>Reeves</surname>
            <given-names>B.C.</given-names>
          </name>
          <name>
            <surname>Wells</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Thuku</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Hamel</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Moran</surname>
            <given-names>J.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both</article-title>
        <source>BMJ</source>
        <volume>358</volume>
        <year>2017</year>
        <object-id pub-id-type="publisher-id">j4008</object-id>
        <pub-id pub-id-type="doi">10.1136/bmj.j4008</pub-id>
      </element-citation>
    </ref>
    <ref id="b0150">
      <label>30</label>
      <element-citation publication-type="journal" id="h0150">
        <person-group person-group-type="author">
          <name>
            <surname>Whiting</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Savovic</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Higgins</surname>
            <given-names>J.P.</given-names>
          </name>
          <name>
            <surname>Caldwell</surname>
            <given-names>D.M.</given-names>
          </name>
          <name>
            <surname>Reeves</surname>
            <given-names>B.C.</given-names>
          </name>
          <name>
            <surname>Shea</surname>
            <given-names>B.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>ROBIS: A new tool to assess risk of bias in systematic reviews was developed</article-title>
        <source>J Clin Epidemiol</source>
        <volume>69</volume>
        <year>2016</year>
        <fpage>225</fpage>
        <lpage>234</lpage>
        <pub-id pub-id-type="doi">10.1016/j.jclinepi.2015.06.005</pub-id>
        <pub-id pub-id-type="pmid">26092286</pub-id>
      </element-citation>
    </ref>
    <ref id="b0155">
      <label>31</label>
      <element-citation publication-type="journal" id="h0155">
        <person-group person-group-type="author">
          <name>
            <surname>Pieper</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Puljak</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Gonzalez-Lorenzo</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Minozzi</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>Minor differences were found between AMSTAR 2 and ROBIS in the assessment of systematic reviews including both randomized and nonrandomized studies</article-title>
        <source>J Clin Epidemiol</source>
        <volume>108</volume>
        <year>2019</year>
        <fpage>26</fpage>
        <lpage>33</lpage>
        <pub-id pub-id-type="doi">10.1016/j.jclinepi.2018.12.004</pub-id>
        <pub-id pub-id-type="pmid">30543911</pub-id>
      </element-citation>
    </ref>
    <ref id="b0160">
      <label>32</label>
      <element-citation publication-type="journal" id="h0160">
        <person-group person-group-type="author">
          <name>
            <surname>Sterne</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Hernán</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Reeves</surname>
            <given-names>B.C.</given-names>
          </name>
          <name>
            <surname>Savović</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Berkman</surname>
            <given-names>N.D.</given-names>
          </name>
          <name>
            <surname>Viswanathan</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions</article-title>
        <source>BMJ</source>
        <volume>355</volume>
        <year>2016</year>
        <object-id pub-id-type="publisher-id">i4919</object-id>
        <pub-id pub-id-type="doi">10.1136/bmj.i4919</pub-id>
      </element-citation>
    </ref>
    <ref id="b0165">
      <label>33</label>
      <element-citation publication-type="journal" id="h0165">
        <person-group person-group-type="author">
          <name>
            <surname>Tendal</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Higgins</surname>
            <given-names>J.P.</given-names>
          </name>
          <name>
            <surname>Juni</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Hrobjartsson</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Trelle</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Nuesch</surname>
            <given-names>E.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Disagreements in meta-analyses using outcomes measured on continuous or rating scales: observer agreement study</article-title>
        <source>BMJ</source>
        <volume>339</volume>
        <year>2009</year>
        <object-id pub-id-type="publisher-id">b3128</object-id>
        <pub-id pub-id-type="doi">10.1136/bmj.b3128</pub-id>
      </element-citation>
    </ref>
    <ref id="b0170">
      <label>34</label>
      <element-citation publication-type="journal" id="h0170">
        <person-group person-group-type="author">
          <name>
            <surname>Gates</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Gates</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Duarte</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Cary</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Becker</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Prediger</surname>
            <given-names>B.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Quality and risk of bias appraisals of systematic reviews are inconsistent across reviewers and centers</article-title>
        <source>J Clin Epidemiol</source>
        <volume>125</volume>
        <year>2020</year>
        <fpage>9</fpage>
        <lpage>15</lpage>
        <pub-id pub-id-type="doi">10.1016/j.jclinepi.2020.04.026</pub-id>
        <pub-id pub-id-type="pmid">32416337</pub-id>
      </element-citation>
    </ref>
    <ref id="b0175">
      <label>35</label>
      <mixed-citation publication-type="other" id="h0175">Boutron I, Page MJ, Higgins J. P. T., Altman DG, Lundh A, Hróbjartsson A. Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane Handbook for Systematic Reviews of Interventions version 60 (updated July 2019): Cochrane; 2019.</mixed-citation>
    </ref>
    <ref id="b0180">
      <label>36</label>
      <element-citation publication-type="journal" id="h0180">
        <person-group person-group-type="author">
          <name>
            <surname>Flemyng</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Dwan</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Moore</surname>
            <given-names>T.H.M.</given-names>
          </name>
          <name>
            <surname>Page</surname>
            <given-names>M.J.</given-names>
          </name>
          <name>
            <surname>Higgins</surname>
            <given-names>J.P.T.</given-names>
          </name>
        </person-group>
        <article-title>Risk of Bias 2 in Cochrane Reviews: a phased approach for the introduction of new methodology</article-title>
        <source>Cochrane Database Syst Rev</source>
        <year>2020;(11).</year>
        <pub-id pub-id-type="doi">10.1002/14651858.ED000148</pub-id>
      </element-citation>
    </ref>
    <ref id="b0185">
      <label>37</label>
      <mixed-citation publication-type="other" id="h0185">Pollock M, Fernandes RM, Becker LA, Pieper D, Hartling L. Chapter V: Overviews of Reviews. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from wwwtrainingcochraneorg/handbook. 2022.</mixed-citation>
    </ref>
    <ref id="b0190">
      <label>38</label>
      <mixed-citation publication-type="other" id="h0190">Interventions CMCM. Overviews of Reviews. n.d. doi: <ext-link ext-link-type="uri" xlink:href="https://methods.cochrane.org/cmi/overviews-of-reviews" id="ir040">https://methods.cochrane.org/cmi/overviews-of-reviews</ext-link>.</mixed-citation>
    </ref>
    <ref id="b0195">
      <label>39</label>
      <element-citation publication-type="journal" id="h0195">
        <person-group person-group-type="author">
          <name>
            <surname>Lunny</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Pieper</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Thabet</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Kanji</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>Managing overlap of primary study results across systematic reviews: practical considerations for authors of overviews of reviews</article-title>
        <source>BMC Med Res Method</source>
        <volume>21</volume>
        <issue>1</issue>
        <year>2021</year>
        <fpage>140</fpage>
        <pub-id pub-id-type="doi">10.1186/s12874-021-01269-y</pub-id>
      </element-citation>
    </ref>
    <ref id="b0200">
      <label>40</label>
      <element-citation publication-type="journal" id="h0200">
        <person-group person-group-type="author">
          <name>
            <surname>Bougioukas</surname>
            <given-names>K.I.</given-names>
          </name>
          <name>
            <surname>Vounzoulaki</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Mantsiou</surname>
            <given-names>C.D.</given-names>
          </name>
          <name>
            <surname>Savvides</surname>
            <given-names>E.D.</given-names>
          </name>
          <name>
            <surname>Karakosta</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Diakonidis</surname>
            <given-names>T.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Methods for depicting overlap in overviews of systematic reviews: An introduction to static tabular and graphical displays</article-title>
        <source>J Clin Epidemiol</source>
        <volume>132</volume>
        <year>2021</year>
        <fpage>34</fpage>
        <lpage>45</lpage>
        <pub-id pub-id-type="doi">10.1016/j.jclinepi.2020.12.004</pub-id>
        <pub-id pub-id-type="pmid">33309886</pub-id>
      </element-citation>
    </ref>
    <ref id="b0205">
      <label>41</label>
      <element-citation publication-type="journal" id="h0205">
        <person-group person-group-type="author">
          <name>
            <surname>Pérez-Bracchiglione</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Meza</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Bangdiwala</surname>
            <given-names>S.I.</given-names>
          </name>
          <name>
            <surname>Niño de Guzmán</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Urrútia</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Bonfill</surname>
            <given-names>X.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Graphical Representation of Overlap for OVErviews: GROOVE tool. Res Synth</article-title>
        <source>Methods</source>
        <volume>13</volume>
        <issue>3</issue>
        <year>2022</year>
        <fpage>381</fpage>
        <lpage>388</lpage>
        <pub-id pub-id-type="doi">10.1002/jrsm.1557</pub-id>
      </element-citation>
    </ref>
    <ref id="b0210">
      <label>42</label>
      <element-citation publication-type="journal" id="h0210">
        <person-group person-group-type="author">
          <name>
            <surname>Jadad</surname>
            <given-names>A.R.</given-names>
          </name>
          <name>
            <surname>Cook</surname>
            <given-names>D.J.</given-names>
          </name>
          <name>
            <surname>Browman</surname>
            <given-names>G.P.</given-names>
          </name>
        </person-group>
        <article-title>A guide to interpreting discordant systematic reviews</article-title>
        <source>CMAJ</source>
        <volume>156</volume>
        <issue>10</issue>
        <year>1997</year>
        <fpage>1411</fpage>
        <lpage>1416</lpage>
        <pub-id pub-id-type="pmid">9164400</pub-id>
      </element-citation>
    </ref>
    <ref id="b0215">
      <label>43</label>
      <element-citation publication-type="journal" id="h0215">
        <person-group person-group-type="author">
          <name>
            <surname>Lunny</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Thirugnanasampanthar</surname>
            <given-names>S.S.</given-names>
          </name>
          <name>
            <surname>Kanji</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Ferri</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Pieper</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Whitelaw</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>How can clinicians choose between conflicting and discordant systematic reviews? A replication study of the Jadad algorithm</article-title>
        <source>BMC Med Res Method</source>
        <volume>22</volume>
        <issue>1</issue>
        <year>2022</year>
        <fpage>276</fpage>
        <pub-id pub-id-type="doi">10.1186/s12874-022-01750-2</pub-id>
      </element-citation>
    </ref>
    <ref id="b0220">
      <label>44</label>
      <element-citation publication-type="journal" id="h0220">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Moss</surname>
            <given-names>J.R.</given-names>
          </name>
          <name>
            <surname>Hiller</surname>
            <given-names>J.E.</given-names>
          </name>
        </person-group>
        <article-title>Applicability and transferability of interventions in evidence-based public health</article-title>
        <source>Health Promot Int</source>
        <volume>21</volume>
        <issue>1</issue>
        <year>2006</year>
        <fpage>76</fpage>
        <lpage>83</lpage>
        <pub-id pub-id-type="doi">10.1093/heapro/dai025</pub-id>
        <pub-id pub-id-type="pmid">16249192</pub-id>
      </element-citation>
    </ref>
    <ref id="b0225">
      <label>45</label>
      <element-citation publication-type="book" id="h0225">
        <person-group person-group-type="author">
          <name>
            <surname>Oliver</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Kavanagh</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Caird</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Lorenc</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Oliver</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Harden</surname>
            <given-names>A.</given-names>
          </name>
          <etal/>
        </person-group>
        <part-title>Health promotion, inequalities and young people's health: a systematic review of research</part-title>
        <year>2008</year>
        <publisher-name>EPPI-Centre, Social Science Research Unit, Institute of Education, University of London</publisher-name>
        <publisher-loc>London</publisher-loc>
      </element-citation>
    </ref>
    <ref id="b0230">
      <label>46</label>
      <element-citation publication-type="book" id="h0230">
        <person-group person-group-type="author">
          <name>
            <surname>Oliver</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Dickson</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Newman</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <part-title>Getting started with a review</part-title>
        <year>2012</year>
        <publisher-name>Sage Publications</publisher-name>
      </element-citation>
    </ref>
    <ref id="b0235">
      <label>47</label>
      <element-citation publication-type="journal" id="h0235">
        <person-group person-group-type="author">
          <name>
            <surname>O'Neill</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Tabish</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Welch</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Petticrew</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Pottie</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Clarke</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health</article-title>
        <source>J Clin Epidemiol</source>
        <volume>67</volume>
        <issue>1</issue>
        <year>2014</year>
        <fpage>56</fpage>
        <lpage>64</lpage>
        <pub-id pub-id-type="doi">10.1016/j.jclinepi.2013.08.005</pub-id>
        <pub-id pub-id-type="pmid">24189091</pub-id>
      </element-citation>
    </ref>
    <ref id="b0240">
      <label>48</label>
      <element-citation publication-type="journal" id="h0240">
        <person-group person-group-type="author">
          <name>
            <surname>Ismail</surname>
            <given-names>S.J.</given-names>
          </name>
          <name>
            <surname>Hardy</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Tunis</surname>
            <given-names>M.C.</given-names>
          </name>
          <name>
            <surname>Young</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Sicard</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Quach</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <article-title>A framework for the systematic consideration of ethics, equity, feasibility, and acceptability in vaccine program recommendations</article-title>
        <source>Vaccine</source>
        <volume>38</volume>
        <issue>36</issue>
        <year>2020</year>
        <fpage>5861</fpage>
        <lpage>5876</lpage>
        <pub-id pub-id-type="doi">10.1016/j.vaccine.2020.05.051</pub-id>
        <pub-id pub-id-type="pmid">32532544</pub-id>
      </element-citation>
    </ref>
    <ref id="b0245">
      <label>49</label>
      <element-citation publication-type="journal" id="h0245">
        <person-group person-group-type="author">
          <name>
            <surname>Ismail</surname>
            <given-names>S.J.</given-names>
          </name>
          <name>
            <surname>Tunis</surname>
            <given-names>M.C.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Quach</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <article-title>Navigating inequities: a roadmap out of the pandemic</article-title>
        <source>BMJ Glob Health</source>
        <volume>6</volume>
        <issue>1</issue>
        <year>2021</year>
        <fpage>e004087</fpage>
      </element-citation>
    </ref>
    <ref id="b0250">
      <label>50</label>
      <element-citation publication-type="journal" id="h0250">
        <person-group person-group-type="author">
          <name>
            <surname>Burchett</surname>
            <given-names>H.E.D.</given-names>
          </name>
          <name>
            <surname>Blanchard</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Kneale</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Thomas</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Assessing the applicability of public health intervention evaluations from one setting to another: a methodological study of the usability and usefulness of assessment tools and frameworks</article-title>
        <source>Health Research Policy and Systems</source>
        <volume>16</volume>
        <issue>1</issue>
        <year>2018</year>
        <fpage>88</fpage>
        <pub-id pub-id-type="doi">10.1186/s12961-018-0364-3</pub-id>
        <pub-id pub-id-type="pmid">30176894</pub-id>
      </element-citation>
    </ref>
  </ref-list>
  <sec id="s0125" sec-type="supplementary-material">
    <label>Appendix A</label>
    <title>Supplementary data</title>
    <p id="p0455">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="m0005"><caption><title>Supplementary data 1</title></caption><media xlink:href="mmc1.docx"/></supplementary-material></p>
  </sec>
  <sec sec-type="data-availability" id="da005">
    <title>Data availability</title>
    <p id="p0020">No data was used for the research described in the article.</p>
  </sec>
  <ack id="ak005">
    <sec id="s0105">
      <title>Acknowledgements</title>
      <p id="p0435">We would like to thank Benntec GmbH and team for developing the e-learning course, which summarizes the steps of the proposed guidance.</p>
    </sec>
    <sec id="s0110">
      <title>Disclaimer</title>
      <p id="p0440">The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated. The funders had no role during the execution, interpretation of the data, or decision to submit this paper for publication.</p>
    </sec>
    <sec id="s0115">
      <title>Funding</title>
      <p id="p0445">This work was supported by the German Federal Ministry of Health through the Global Health Protection Program (Grant No: ZM I 5 2519GHP713).</p>
    </sec>
  </ack>
  <fn-group>
    <fn id="s0120" fn-type="supplementary-material">
      <label>Appendix A</label>
      <p id="p0450">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.vaccine.2023.02.027" id="ir020">https://doi.org/10.1016/j.vaccine.2023.02.027</ext-link>.</p>
    </fn>
  </fn-group>
</back>
